12 Sept 2025
16m
Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.